Headlines about BIOLASE (NASDAQ:BIOL) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BIOLASE earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news stories about the medical technology company an impact score of 45.9891673948295 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, ValuEngine upgraded shares of BIOLASE from a “sell” rating to a “hold” rating in a research note on Monday, October 2nd.

Shares of BIOLASE (NASDAQ:BIOL) traded up $0.01 during trading on Tuesday, hitting $0.46. 171,000 shares of the stock traded hands, compared to its average volume of 217,720. The stock has a market cap of $33.45, a PE ratio of -1.39 and a beta of 2.31. BIOLASE has a 1-year low of $0.28 and a 1-year high of $1.87.

In other BIOLASE news, major shareholder Larry N. Feinberg purchased 12,545,615 shares of the company’s stock in a transaction dated Tuesday, December 5th. The shares were acquired at an average price of $0.43 per share, for a total transaction of $5,394,614.45. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 7.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/biolase-biol-receiving-somewhat-favorable-press-coverage-analysis-shows/1800071.html.

BIOLASE Company Profile

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.

Insider Buying and Selling by Quarter for BIOLASE (NASDAQ:BIOL)

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with Analyst Ratings Network's FREE daily email newsletter.